Table 1 Demographics and characteristics of treated patients
N (%)a | |
|---|---|
Total number | 28 (100) |
Sex | |
Female | 28 (100) |
Age (years) | |
Mean | 62.5 |
Median | 64 |
Range | 40–82 |
Baseline ECOG performance status | |
0 | 16 (57) |
1 | 8 (29) |
2b | 4 (14) |
Progesterone receptor positive | 20 (71) |
Estrogen receptor positive | 27 (96) |
HER2 status | |
HER2 positive | 3 (11) |
HER2 negative | 20 (71) |
HER2 unknown or missing | 5 (18) |
Prior therapies | |
Chemotherapy | 24 (86) |
Prior adjuvant or neoadjuvant chemotherapy | |
Yes | 19 (68) |
No | 9 (32) |
Number of prior metastatic chemotherapies | |
0 | 18 (64) |
1 | 9 (32) |
≥2 | 1 (4) |
Hormone therapy prior to letrozole | 28 (100) |
Prior adjuvant radiotherapy | |
Yes | 16 (57) |
No | 12 (43) |
Number of prior metastatic radiotherapies | |
0 | 16 (57) |
1 | 7 (25) |
≥2 | 7 (18) |